Literature DB >> 31097877

Use of a colorimetric assay to evaluate the proliferation of canine mammary tumor cells exposed to propofol.

Martina Argano1, Raffaella De Maria1, Katrin Rodlsberger1, Paolo Buracco1, M Paula Larenza Menzies1.   

Abstract

Drugs applied on human cancer cells can influence the rate of cell proliferation. The present study investigates the use of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) colorimetric assay to evaluate canine tumor cell proliferation after exposure to the injectable anesthetic, propofol. Primary (CIPp) and metastatic (CIPm) canine tubular adenocarcinoma cell lines were incubated with cell culture medium (control) or propofol (1, 5, and 10 μg/mL). The MTT assays were performed after 6 and 12 hours of exposure. Measurements of absorbance were obtained for each condition with a spectrophotometer and compared with controls using a 3-way analysis of variance (P < 0.05). An increased cell proliferation rate was observed in CIPp exposed to 5 and 10 μg/mL of propofol for 6 hours and 1, 5, and 10 μg/mL for 12 hours. No significant changes were observed in CIPm after 6 hours of exposure. All propofol concentrations decreased the cell proliferation rate in CIPm after 12 hours of exposure. The MTT assays showed that exposure of CIPp to propofol for 6 and 12 hours increased cell proliferation. A decrease in the CIPm proliferation rate was observed when propofol exposure lasted for 12 hours. Further studies are warranted to better understand the role of propofol on cancer cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31097877      PMCID: PMC6450161     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  22 in total

1.  The 2000 EBCTCG overview: a widening gap.

Authors:  S Chia; C Bryce; K Gelmon
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

2.  The MTT-assay as a rapid test for cell proliferation and cell killing: application to human peripheral blood lymphocytes (PBL).

Authors:  H Weichert; I Blechschmidt; S Schröder; H Ambrosius
Journal:  Allerg Immunol (Leipz)       Date:  1991

3.  Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression.

Authors:  R Uyama; T Nakagawa; S-H Hong; M Mochizuki; R Nishimura; N Sasaki
Journal:  Vet Comp Oncol       Date:  2006-06       Impact factor: 2.613

4.  Cell sensitivity assays: the MTT assay.

Authors:  Johan van Meerloo; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Methods Mol Biol       Date:  2011

5.  COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer.

Authors:  Felisbina L Queiroga; Isabel Pires; Margarida Parente; Hugo Gregório; Carlos S Lopes
Journal:  Vet J       Date:  2010-08-02       Impact factor: 2.688

6.  Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study.

Authors:  J M Hughes; A M Nolan
Journal:  Vet Surg       Date:  1999 Nov-Dec       Impact factor: 1.495

7.  Effects of propofol on proliferation and anti-apoptosis of neuroblastoma SH-SY5Y cell line: new insights into neuroprotection.

Authors:  Gong-Jhe Wu; Wu-Fu Chen; Han-Chun Hung; Yen-Hsuan Jean; Chun-Sung Sung; Chiranjib Chakraborty; Hsin-Pai Lee; Nan-Fu Chen; Zhi-Hong Wen
Journal:  Brain Res       Date:  2011-02-25       Impact factor: 3.252

8.  Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro.

Authors:  C A Deegan; D Murray; P Doran; P Ecimovic; D C Moriarty; D J Buggy
Journal:  Br J Anaesth       Date:  2009-09-22       Impact factor: 9.166

9.  Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.

Authors:  Joanna S Morris; Colin Nixon; Oliver J A King; Iain M Morgan; Adrian W Philbey
Journal:  Vet J       Date:  2008-03-07       Impact factor: 2.688

10.  Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells.

Authors:  Rafat A Siddiqui; Mustapha Zerouga; Min Wu; Alicia Castillo; Kevin Harvey; Gary P Zaloga; William Stillwell
Journal:  Breast Cancer Res       Date:  2005-06-07       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.